carfilzomib,lenalidomide,dexamethasone
amgen
['mmsm', 'atlas']
congress | #eha2022 | dominik dytfeld presents results of atlas trial, the first phase 3 trial investigating post-transplant krd vs len maintenance in #myeloma - pfs: 59 months with krd (vs 41 months with len)
- os benefit and qol need longer-term follow-up #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma